Sources | Names Used |
---|---|
CTRPv2 | crizotinib:PLX-4032 (2:1 mol/mol) |
PharmacoGx | crizotinib:PLX-4032 (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | ARF4 | CTRPv2 | pan-cancer | AAC | -0.098 | 0.01 |
mRNA | TRIM3 | CTRPv2 | pan-cancer | AAC | -0.098 | 0.01 |
mRNA | FLII | CTRPv2 | pan-cancer | AAC | -0.089 | 0.01 |
mRNA | SIL1 | CTRPv2 | pan-cancer | AAC | -0.086 | 0.01 |
mRNA | CYLD | CTRPv2 | pan-cancer | AAC | -0.091 | 0.01 |
mRNA | TNR | CTRPv2 | pan-cancer | AAC | 0.082 | 0.01 |
mRNA | ANKRD6 | CTRPv2 | pan-cancer | AAC | -0.085 | 0.01 |
mRNA | ARL5B | CTRPv2 | pan-cancer | AAC | 0.088 | 0.01 |
mRNA | IQCF1 | CTRPv2 | pan-cancer | AAC | 0.083 | 0.01 |
mRNA | TDRD3 | CTRPv2 | pan-cancer | AAC | 0.087 | 0.01 |